SCHEMBL178554

SCHEMBL178554

CNC(C)c1ccc(OC)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.60
CA2 P00918 2/20 0.60
CA1 P00915 1/20 0.60
CYP2D6 P10635 1/20 0.53
HPGD P15428 1/20 0.51
KDM1A O60341 1/20 0.50
ALDH1A1 P00352 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 1/20 0.49
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
CYP1A2 P05177 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3657271 0.98 ACHE (0.58) ACHECA2CA1CYP2D6HPGD
SCHEMBL17113704 0.85 CYP2D6 (0.46) ACHECA2CA1CYP2D6HPGD
SCHEMBL14318777 0.85 CYP2D6 (0.50) ACHECA2CA1CYP2D6HPGD
Hydrochloric Acid SCHEMBL5774500 0.84 ACHE (0.60) ACHECA2CA1HPGDKDM1A
SCHEMBL19790002 0.84 KDM4E (0.47) ACHECA2CA1CYP2D6HPGD
SCHEMBL10189787 0.83 CYP2D6 (0.45) ACHECA2CA1CYP2D6HPGD
SCHEMBL178499 0.83 CYP2D6 (0.49) ACHECA2CA1CYP2D6HPGD
SCHEMBL2668984 0.83 TAS1R3 (0.49) ACHECA2CA1CYP2D6ALDH1A1
SCHEMBL9781293 0.82 ACHE (0.58) ACHECA2CA1HPGDKDM1A
SCHEMBL12870325 0.82 ACHE (0.58) ACHECA2CA1HPGDKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222629-A1 PROCESS FOR PREPARING N-METHYL-3, 4 DIMETHOXYPHENYLETHYLAMINE Sicor, Inc. (US) 2010-09-01 EP claimed
WO-2009086464-A1 PROCESS FOR PREPARING N-METHYL-3, 4 DIMETHOXYPHENYLETHYLAMINE SICOR INC. (US) 2009-07-09 WO claimed
US-20090171110-A1 PROCESS FOR PREPARING N-METHYL-3, 4-DIMETHOXYPHENYLETHYLAMINE SICOR INC. 2009-07-02 US claimed
EP-0389876-B1 NEW PROCESS FOR THE SYNTHESIS OF THE N-METHYL-3,4-DIMETHOXYPHENYLETHYLAMINE Alfa Chemicals Italiana S.r.l. (IT) 1993-08-04 EP claimed
US-5057624-A PROCESS FOR THE SYNTHESIS OF THE N-METHYL-3,4-DIMETHOXYPHENYLETHYLAMINE ALFA WASSERMANN S.P.A. (IT) 1991-10-15 US claimed
EP-0389876-A1 New process for the synthesis of the N-methyl-3,4-dimethoxyphenylethylamine Alfa Chemicals Italiana S.r.l. (IT) 1990-10-03 EP claimed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-03-07 US disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
EP-2295436-A1 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors Bayer Schering Pharma AG (DE) 2011-03-16 EP disclosed
US-20110009367-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-13 US disclosed
EP-2222629-A1 PROCESS FOR PREPARING N-METHYL-3, 4 DIMETHOXYPHENYLETHYLAMINE Sicor, Inc. (US) 2010-09-01 EP disclosed
US-7704999-B2 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-27 US disclosed
US-4833162-A Substituted benzeneacetonitriles and their use as calcium channel blockers AMERICAN CYANAMID COMPANY (US) 1989-05-23 US disclosed
US-4723039-A CARDIOVASCULAR DISORDERS; ULCERS BASF AKTIENGESELLSCHAFT (DE) 1988-02-02 US disclosed
CN-85101312-A Process for preparing Benzothiazine derivatives 1987-04-08 CN disclosed
US-4137318-A HYPOTENSIVES AND HEART RATE REDUCERS BOEHRINGER INGELHEIM GMBH (DE) 1979-01-30 US disclosed
US-4134980-A Phenylalkylamino-alkyl derivatives of quinazolinone and phthalazinone BOEHRINGER INGELHEIM GMBH (DE) 1979-01-16 US disclosed
US-4087541-A REDUCING HEART RATE BOEHRINGER INGELHEIM GMBH (DT) 1978-05-02 US disclosed
US-4038407-A HEART RATE SLOWING DRUGS BOEHRINGER INGELHEIM GMBH (DT) 1977-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090171110-A1 PROCESS FOR PREPARING N-METHYL-3, 4-DIMETHOXYPHENYLETHYLAMINE PNMT, COMT, TET3 ACHE 425/4885CA2 2920/4885CA1 4460/4885
US-20110009367-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE2A ACHE 203/4885CA2 1494/4885CA1 4584/4885
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE2A ACHE 203/4885CA2 1494/4885CA1 4584/4885
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 ACHE 3347/4885CA2 314/4885CA1 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.